SynthesisCancer medicine2026
Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Synthesis in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis umbrella review summarizes evidence from systematic reviews and meta-analyses on the efficacy and safety of immune checkpoint inhibitors (ICIs) in hematologic malignancies. To our knowledge, this is the first umbrella review to comprehensively evaluate ICIs across multiple hematologic cancers. The goal is to clarify their therapeutic potential, highlight major safety issues, and provide evidence-based guidance for future clinical and research applications.
methodsA comprehensive search was conducted across PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews up to May 2025. Systematic reviews and meta-analyses investigating ICIs in hematologic malignancies were included. The AMSTAR tool was used to assess methodological quality, and the GRADE system was employed to evaluate the quality of evidence for each outcome.
resultsA total of 24 meta-analyses met the inclusion criteria, covering 39 unique interventions. ICIs demonstrated significant efficacy in multiple myeloma (MM), relapsed/refractory natural killer T-cell lymphoma (R/R NKT), relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and relapsed/refractory primary mediastinal B-cell lymphoma (R/R PMBCL). Pembrolizumab combined with lenalidomide and dexamethasone (PLD) significantly improved overall survival (OS) in MM (HR: 0.51, 95% CI: 0.32 to 0.82, high quality). In R/R NKT, sintilimab and other ICIs showed moderate overall response rates (ORR) with favorable safety profiles. Pembrolizumab also demonstrated moderate efficacy in R/R CLL and R/R PMBCL, with low rates of severe adverse events. However, the studies exhibited significant heterogeneity, and publication bias was detected in certain outcomes, highlighting the need for cautious interpretation.
conclusionsICIs show promising therapeutic potential in several hematologic malignancies, particularly R/R NKT, MM, R/R CLL, and R/R PMBCL. While safety profiles are generally favorable, certain regimens are associated with manageable toxicities. Future research should focus on optimizing combination therapies, refining patient selection criteria, and addressing study heterogeneity to enhance the clinical application of ICIs in hematologic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.